Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells 97,244 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 97,244 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $13.56, for a total transaction of $1,318,628.64. Following the transaction, the director now directly owns 210,346 shares in the company, valued at approximately $2,852,291.76. The trade was a 31.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Laura Shawver also recently made the following trade(s):

• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total value of $203,115.00.

ARS Pharmaceuticals Trading Up 0.1 %

NASDAQ SPRY opened at $14.02 on Friday. The stock’s fifty day moving average price is $14.79 and its 200-day moving average price is $12.21. The stock has a market cap of $1.36 billion, a P/E ratio of -27.49 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 12 month low of $5.01 and a 12 month high of $18.51.

Analysts Set New Price Targets

SPRY has been the subject of a number of research analyst reports. Raymond James upgraded ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Leerink Partners boosted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, ARS Pharmaceuticals currently has an average rating of “Buy” and an average target price of $24.00.

Institutional Trading of ARS Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. J.W. Cole Advisors Inc. raised its holdings in ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after buying an additional 1,500 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of ARS Pharmaceuticals during the third quarter valued at approximately $30,000. Creative Planning raised its holdings in ARS Pharmaceuticals by 7.0% in the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after acquiring an additional 2,307 shares during the last quarter. HighTower Advisors LLC lifted its position in ARS Pharmaceuticals by 18.2% in the 3rd quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after acquiring an additional 4,369 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after purchasing an additional 4,472 shares during the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.